Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PDL Biopharma discloses hostile bid to acquire Neos for $10.25/share; proposal later terminated

Executive Summary

PDL BioPharma Inc. made public its launch of a hostile bid to acquire Nasdaq-traded Neos Therapeutics Inc. (modified-release oral drug delivery platform) for $10.25 in cash per share (a 32% premium to the previous 10-day closing average to the October announcement date).

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Controlled Release
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash for Equity

Related Companies